Etoposide induces more severe mucositis than CY when added to TBI as conditioning in allograft recipients receiving CsA and MTX

[1]  G. Behre,et al.  Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients , 2008, Bone Marrow Transplantation.

[2]  J. Szer,et al.  Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants , 2008, Bone Marrow Transplantation.

[3]  W. Jędrzejczak,et al.  The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant , 2007, Bone Marrow Transplantation.

[4]  J. Szer,et al.  A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic stem cell transplantation , 2007, Bone Marrow Transplantation.

[5]  D. McGuire,et al.  Clinical Practice Guidelines for the Prevention and Treatment of Mucositis , 2007 .

[6]  Mei-Jie Zhang,et al.  A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  T. Shea,et al.  Palifermin for oral mucositis after intensive therapy for hematologic cancers , 2017 .

[8]  C. Ulrich,et al.  Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Epstein,et al.  Quality of life, taste, olfactory and oral function following high-dose chemotherapy and allogeneic hematopoietic cell transplantation , 2002, Bone Marrow Transplantation.

[10]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  C A Squier,et al.  Biology of oral mucosa and esophagus. , 2001, Journal of the National Cancer Institute. Monographs.

[12]  C. Wenzel,et al.  Oral Mucositis Complicating Chemotherapy and/or Radiotherapy: Options for Prevention and Treatment , 2001, CA: a cancer journal for clinicians.

[13]  F. Spijkervet,et al.  Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Goormastic,et al.  Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma , 2000, Bone Marrow Transplantation.

[15]  B. D. de Pauw,et al.  Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview , 2000, Bone Marrow Transplantation.

[16]  L. Constine,et al.  Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  B. Dubray,et al.  Radiobiological and Clinical Bases for Total Body Irradiation in the Leukemias and Lymphomas. , 1995, Seminars in radiation oncology.

[18]  O. S. Nielsen,et al.  The effect of sequence and time interval between cyclophosphamide and total body irradiation on lung and bone marrow damage following bone marrow transplantation in mice. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  H. Deeg,et al.  Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. , 1989, Blood.

[20]  N. Schmitz,et al.  Fractionated total body irradiation and high-dose VP 16-213 followed by allogeneic bone marrow transplantation in advanced leukemias. , 1988, Blood.

[21]  J. Doroshow,et al.  Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies [published erratum appears in Blood 1987 Jun;69(6):1789] , 1987 .

[22]  D. Findley,et al.  Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. , 1987, Blood.

[23]  N. Mulder,et al.  High-dose teniposide for refractory malignancies: a phase I study. , 1986, Cancer treatment reports.

[24]  E. de Vries,et al.  High-dose etoposide for refractory malignancies: a phase I study. , 1984, Cancer treatment reports.

[25]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.